Medical Cannabis for Arthritis in the UK

Cannabis targets arthritis pain through multiple mechanisms, which is why it often works where single-target pharmaceuticals fail. The two main cannabinoids — THC and CBD — interact with the endocannabinoid system in ways that are particularly relevant to arthritic pain and inflammation.

CB1 receptors are concentrated in the central nervous system and spinal cord. When THC binds to these receptors, it modulates pain signalling at the spinal and supraspinal levels — essentially turning down the volume on pain signals before they reach conscious perception. This is why cannabis is particularly effective for the central sensitisation component of chronic arthritis pain.

CB2 receptors are found primarily on immune cells. Both THC and CBD activate CB2 receptors, leading to reduced production of pro-inflammatory cytokines like TNF-alpha, IL-6, and IL-1 beta. In osteoarthritis, where low-grade inflammation drives cartilage degradation, this anti-inflammatory effect can slow disease progression. A 2024 in-vitro study using human chondrocytes found that CBD reduced inflammatory markers by 40% compared to controls, with no cytotoxic effects.

Cannabis also acts on non-cannabinoid targets relevant to arthritis. CBD activates TRPV1 receptors (the same target as capsaicin) to modulate pain perception, while THC activates PPAR-gamma receptors involved in inflammation regulation. This multi-target pharmacology explains why many arthritis patients report better results with whole-plant cannabis than with isolated compounds.

The evidence base for cannabis in arthritis has expanded considerably. Here is what the best studies show across different arthritic conditions:

Osteoarthritis

A 2025 randomised controlled trial of 420 patients with knee osteoarthritis found that a 10mg THC / 10mg CBD combination oil reduced pain scores by 31% over 12 weeks compared to 14% with placebo — a statistically and clinically significant difference. Notably, the treatment group also showed improved physical function scores on the WOMAC index, suggesting the pain relief translated to real-world mobility gains.

Rheumatoid Arthritis

A 2024 systematic review of cannabinoids for inflammatory arthritis analysed 8 trials with 1,261 participants. The findings showed consistent improvement in pain scores, morning stiffness duration, and disease activity scores (DAS-28) among patients using cannabinoid-based medicines. The effect was strongest for pain at rest and sleep disturbance — two of the most debilitating RA symptoms.

Chronic Pain More Broadly

A 2026 meta-analysis of 21 RCTs on cannabis for chronic pain found a number needed to treat (NNT) of 8 for a 30% reduction in pain — comparable to NSAIDs and better than gabapentinoids. The NNT for opioids is 4-5, but the safety profile of cannabis for long-term use is significantly more favourable.

The evidence is not without limitations. Most trials are short-term (4-12 weeks), and there is minimal data on disease-modifying effects over years of use. Blinding is also difficult — patients can tell when they have received THC, introducing potential bias in subjective outcomes. Despite these caveats, the direction of evidence is consistent: cannabinoids reduce pain and improve function in arthritis patients.

Accessing medical cannabis for arthritis in the UK is possible but requires navigating a specific clinical pathway. Since November 2018, specialist doctors on the General Medical Council's specialist register can prescribe cannabis-based medicinal products — but this does not include GPs, who are not permitted to initiate or manage cannabis prescriptions.

Arthritis itself is not explicitly listed as a qualifying condition under NICE guidelines for cannabis-based medicines. However, chronic pain is, and many arthritis patients are accepted into UK clinic programmes under the broader chronic pain category. The key is that the pain must be refractory — meaning it has not responded adequately to at least two conventional treatments.

The typical pathway involves: (1) a referral from your GP or a self-referral to a private specialist clinic, (2) a consultation with a pain specialist or rheumatologist who is on the GMC specialist register, (3) review of your medical records and treatment history, and (4) a prescription if the specialist determines cannabis is appropriate. The NHS has prescribed cannabis-based medicines to fewer than 5 arthritis patients as of 2025 — virtually all access is through private clinics at £50-£250 per consultation, plus £150-£500 per month for medication.

Major UK clinics accepting chronic pain patients include Sapphire Medical, Releaf, Integro, and Mamedica. Most require proof of previous treatment failure, a recent clinic letter, and a clear understanding of the risks and benefits. Approval rates for chronic pain applications range from 60-80% depending on the clinic and the strength of the patient's medical history.

Arthritis patients have several options for cannabis administration, each with distinct advantages depending on the type and location of pain.

Oils and Tinctures

These are the most common choice for arthritis patients in UK clinics. Sublingual oils offer systemic relief that lasts 4-8 hours, making them ideal for all-day pain management. A typical starting protocol is 5-10mg CBD with 2-5mg THC twice daily, titrated upward over 2-4 weeks. The advantage is consistent blood levels and easy dose adjustment. The disadvantage is slow onset (30-90 minutes) and lower bioavailability (10-20%) compared to inhalation.

Flower / Vaporisation

Inhaled cannabis provides rapid relief within minutes, making it useful for breakthrough pain and morning stiffness. UK clinics can prescribe dried flower for vaporisation at temperatures of 160-210°C. The advantage is fast-acting relief and the ability to fine-tune dose in real-time. The disadvantage is shorter duration (1-3 hours) and the need to inhale, which is not suitable for all patients.

Topicals

CBD and THC-infused creams, balms, and patches can be applied directly to affected joints. Topicals work primarily on peripheral cannabinoid receptors in the skin and underlying tissues without entering the bloodstream in significant amounts — meaning no psychoactive effects. A 2024 study of a CBD topical for hand osteoarthritis found a 35% reduction in pain scores after 4 weeks of twice-daily application. Topicals are particularly useful for patients who want localised relief without any intoxication.

Dosing Strategy for Arthritis

The standard recommendation is 'start low, go slow.' Begin with a CBD-dominant product (20:1 or 10:1 CBD:THC ratio) at low doses, and gradually increase the THC proportion if needed for pain control. Many arthritis patients stabilise on a 2:1 or 1:1 ratio with total daily cannabinoid doses of 20-80mg. Consistent dosing at the same times each day appears more effective than as-needed use for chronic pain.